supra mic Search Results


supra mic  (ATCC)
99
ATCC supra mic
Supra Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/supra+mic/MIC/pm29044318-93-5-19
Average 99 stars, based on 1 article reviews
supra mic - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
supra mic concentration  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology supra mic concentration
Supra Mic Concentration, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/supra+mic/Miconazole/bio_rxiv__2024__11__09__622705-169-38-43
Average 93 stars, based on 1 article reviews
supra mic concentration - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
mic  (ATCC)
96
ATCC mic
β-Lactam MICs for strains of S. <t> pneumoniae </t> used in time-kill studies with concentrations of antibiotics achievable in MEF
Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/supra+mic/Streptococcus+Pneumoniae/pmc00105718-148-59-69
Average 96 stars, based on 1 article reviews
mic - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
non toxic  (ATCC)
99
ATCC non toxic
β-Lactam MICs for strains of S. <t> pneumoniae </t> used in time-kill studies with concentrations of antibiotics achievable in MEF
Non Toxic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/supra+mic/Acinetobacter+baumannii+Bouvet+and+Grimont/pm21251823-76-5-16
Average 99 stars, based on 1 article reviews
non toxic - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
quartz suprasil micro cell without lid  (PerkinElmer)
N/A
   Buy from Supplier
nir quartz suprasil 300 rectangular semi-micro cell with lid  (PerkinElmer)
N/A
   Buy from Supplier
quartz suprasil micro cell with stopper  (PerkinElmer)
N/A
Micro Cells has similar outside dimensions to Macro cells. Their walls, however, have been thickened, which limits the interior sample chamber width. This significantly reduces the amount of sample needed for analysis. Qty. 2.
   Buy from Supplier
uv quartz suprasil rectangular semi-micro cell with lid  (PerkinElmer)
N/A
   Buy from Supplier
uv quartz suprasil rectangular semi-micro cell with stopper  (PerkinElmer)
N/A
   Buy from Supplier
uv quartz suprasil rectangular micro cell with ptfe stopper  (PerkinElmer)
N/A
   Buy from Supplier
uv quartz suprasil rectangular flow-through cell, semi-micro/ultra-micro with in- and outlet tubes  (PerkinElmer)
N/A
   Buy from Supplier
suprmix cumar p-25 chemical  (BOC Sciences)
N/A
   Buy from Supplier

Image Search Results


β-Lactam MICs for strains of S. pneumoniae used in time-kill studies with concentrations of antibiotics achievable in MEF

Journal:

Article Title: In Vitro Activities of Oral ?-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

doi:

Figure Lengend Snippet: β-Lactam MICs for strains of S. pneumoniae used in time-kill studies with concentrations of antibiotics achievable in MEF

Article Snippet: Following exposure to cefpodoxime, however, S. pneumoniae ATCC 6303 showed a fourfold decrease in susceptibility to this compound (Table ), whereas the culture passaged in cefuroxime not only was fourfold less susceptible to cefuroxime but was also fourfold less susceptible to cefpodoxime and cefixime. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 S. pneumoniae strain and source a MIC (μg/ml) Amoxicillin Amoxicillin-clavulanate b Cefuroxime Cefpodoxime Cefaclor Cefixime Loracarbef ATCC 6303 (parent) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin (0.015) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin-clavulanate b (0.015) 0.015 0.03 0.015 0.03 0.5 0.25 0.5 Cefpodoxime (0.12) 0.015 0.03 0.015 0.12 c 0.5 0.25 0.5 Cefuroxime (0.12) 0.03 0.03 0.12 0.12 2 1.0 1.0 Cefaclor (2) 0.015 0.015 0.03 0.03 1.0 0.25 1.0 Loracarbef (0.5) 0.03 0.03 0.03 0.03 2 0.25 1.0 Cefixime (0.5) 0.008 0.015 0.03 0.25 0.5 0.25 0.5 5303 (parent) 0.008 0.008 0.015 0.015 0.5 0.12 0.5 Amoxicillin (0.015) 0.008 0.015 0.03 0.015 0.5 0.12 0.5 Amoxicillin-clavulanate b (0.002) 0.008 0.015 0.015 0.015 1.0 0.12 0.5 Cefpodoxime (0.03) 0.015 0.015 0.12 0.06 0.5 0.5 2 Cefuroxime (0.5) 0.008 0.008 0.5 0.12 2 2 4 Cefaclor (1.0) 0.008 0.015 0.015 0.015 0.5 0.12 0.5 Loracarbef (0.5) 0.008 0.015 0.015 0.03 0.5 0.25 1.0 Cefixime (0.25) 0.015 0.03 0.03 0.03 1.0 0.25 1.0 Open in a separate window a Expressed as the antibiotic and concentration (in micrograms per milliliter) from which it was isolated. b Tested at a 2:1 ratio and expressed as the concentration of amoxicillin. c Boldface values indicate a fourfold or greater increase in the MIC compared with that for the parent strain.

Techniques:

Comparative activities of 10 orally available β-lactam compounds against S. pneumoniae a

Journal:

Article Title: In Vitro Activities of Oral ?-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

doi:

Figure Lengend Snippet: Comparative activities of 10 orally available β-lactam compounds against S. pneumoniae a

Article Snippet: Following exposure to cefpodoxime, however, S. pneumoniae ATCC 6303 showed a fourfold decrease in susceptibility to this compound (Table ), whereas the culture passaged in cefuroxime not only was fourfold less susceptible to cefuroxime but was also fourfold less susceptible to cefpodoxime and cefixime. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 S. pneumoniae strain and source a MIC (μg/ml) Amoxicillin Amoxicillin-clavulanate b Cefuroxime Cefpodoxime Cefaclor Cefixime Loracarbef ATCC 6303 (parent) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin (0.015) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin-clavulanate b (0.015) 0.015 0.03 0.015 0.03 0.5 0.25 0.5 Cefpodoxime (0.12) 0.015 0.03 0.015 0.12 c 0.5 0.25 0.5 Cefuroxime (0.12) 0.03 0.03 0.12 0.12 2 1.0 1.0 Cefaclor (2) 0.015 0.015 0.03 0.03 1.0 0.25 1.0 Loracarbef (0.5) 0.03 0.03 0.03 0.03 2 0.25 1.0 Cefixime (0.5) 0.008 0.015 0.03 0.25 0.5 0.25 0.5 5303 (parent) 0.008 0.008 0.015 0.015 0.5 0.12 0.5 Amoxicillin (0.015) 0.008 0.015 0.03 0.015 0.5 0.12 0.5 Amoxicillin-clavulanate b (0.002) 0.008 0.015 0.015 0.015 1.0 0.12 0.5 Cefpodoxime (0.03) 0.015 0.015 0.12 0.06 0.5 0.5 2 Cefuroxime (0.5) 0.008 0.008 0.5 0.12 2 2 4 Cefaclor (1.0) 0.008 0.015 0.015 0.015 0.5 0.12 0.5 Loracarbef (0.5) 0.008 0.015 0.015 0.03 0.5 0.25 1.0 Cefixime (0.25) 0.015 0.03 0.03 0.03 1.0 0.25 1.0 Open in a separate window a Expressed as the antibiotic and concentration (in micrograms per milliliter) from which it was isolated. b Tested at a 2:1 ratio and expressed as the concentration of amoxicillin. c Boldface values indicate a fourfold or greater increase in the MIC compared with that for the parent strain.

Techniques:

Agar dilution MICs of test β-lactams for isolates of S. pneumoniae ATCC 6303 and S. pneumoniae 5303 following five serial passages through increasing antibiotic concentrations

Journal:

Article Title: In Vitro Activities of Oral ?-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

doi:

Figure Lengend Snippet: Agar dilution MICs of test β-lactams for isolates of S. pneumoniae ATCC 6303 and S. pneumoniae 5303 following five serial passages through increasing antibiotic concentrations

Article Snippet: Following exposure to cefpodoxime, however, S. pneumoniae ATCC 6303 showed a fourfold decrease in susceptibility to this compound (Table ), whereas the culture passaged in cefuroxime not only was fourfold less susceptible to cefuroxime but was also fourfold less susceptible to cefpodoxime and cefixime. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 S. pneumoniae strain and source a MIC (μg/ml) Amoxicillin Amoxicillin-clavulanate b Cefuroxime Cefpodoxime Cefaclor Cefixime Loracarbef ATCC 6303 (parent) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin (0.015) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin-clavulanate b (0.015) 0.015 0.03 0.015 0.03 0.5 0.25 0.5 Cefpodoxime (0.12) 0.015 0.03 0.015 0.12 c 0.5 0.25 0.5 Cefuroxime (0.12) 0.03 0.03 0.12 0.12 2 1.0 1.0 Cefaclor (2) 0.015 0.015 0.03 0.03 1.0 0.25 1.0 Loracarbef (0.5) 0.03 0.03 0.03 0.03 2 0.25 1.0 Cefixime (0.5) 0.008 0.015 0.03 0.25 0.5 0.25 0.5 5303 (parent) 0.008 0.008 0.015 0.015 0.5 0.12 0.5 Amoxicillin (0.015) 0.008 0.015 0.03 0.015 0.5 0.12 0.5 Amoxicillin-clavulanate b (0.002) 0.008 0.015 0.015 0.015 1.0 0.12 0.5 Cefpodoxime (0.03) 0.015 0.015 0.12 0.06 0.5 0.5 2 Cefuroxime (0.5) 0.008 0.008 0.5 0.12 2 2 4 Cefaclor (1.0) 0.008 0.015 0.015 0.015 0.5 0.12 0.5 Loracarbef (0.5) 0.008 0.015 0.015 0.03 0.5 0.25 1.0 Cefixime (0.25) 0.015 0.03 0.03 0.03 1.0 0.25 1.0 Open in a separate window a Expressed as the antibiotic and concentration (in micrograms per milliliter) from which it was isolated. b Tested at a 2:1 ratio and expressed as the concentration of amoxicillin. c Boldface values indicate a fourfold or greater increase in the MIC compared with that for the parent strain.

Techniques:

MICs for S. pneumoniae 1320b following treatment with simulated concentrations of amoxicillin, amoxicillin-clavulanate, cefuroxime, and cefpodoxime achieved in the serum of humans

Journal:

Article Title: In Vitro Activities of Oral ?-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

doi:

Figure Lengend Snippet: MICs for S. pneumoniae 1320b following treatment with simulated concentrations of amoxicillin, amoxicillin-clavulanate, cefuroxime, and cefpodoxime achieved in the serum of humans

Article Snippet: Following exposure to cefpodoxime, however, S. pneumoniae ATCC 6303 showed a fourfold decrease in susceptibility to this compound (Table ), whereas the culture passaged in cefuroxime not only was fourfold less susceptible to cefuroxime but was also fourfold less susceptible to cefpodoxime and cefixime. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 S. pneumoniae strain and source a MIC (μg/ml) Amoxicillin Amoxicillin-clavulanate b Cefuroxime Cefpodoxime Cefaclor Cefixime Loracarbef ATCC 6303 (parent) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin (0.015) 0.03 0.03 0.03 0.03 2 0.25 1.0 Amoxicillin-clavulanate b (0.015) 0.015 0.03 0.015 0.03 0.5 0.25 0.5 Cefpodoxime (0.12) 0.015 0.03 0.015 0.12 c 0.5 0.25 0.5 Cefuroxime (0.12) 0.03 0.03 0.12 0.12 2 1.0 1.0 Cefaclor (2) 0.015 0.015 0.03 0.03 1.0 0.25 1.0 Loracarbef (0.5) 0.03 0.03 0.03 0.03 2 0.25 1.0 Cefixime (0.5) 0.008 0.015 0.03 0.25 0.5 0.25 0.5 5303 (parent) 0.008 0.008 0.015 0.015 0.5 0.12 0.5 Amoxicillin (0.015) 0.008 0.015 0.03 0.015 0.5 0.12 0.5 Amoxicillin-clavulanate b (0.002) 0.008 0.015 0.015 0.015 1.0 0.12 0.5 Cefpodoxime (0.03) 0.015 0.015 0.12 0.06 0.5 0.5 2 Cefuroxime (0.5) 0.008 0.008 0.5 0.12 2 2 4 Cefaclor (1.0) 0.008 0.015 0.015 0.015 0.5 0.12 0.5 Loracarbef (0.5) 0.008 0.015 0.015 0.03 0.5 0.25 1.0 Cefixime (0.25) 0.015 0.03 0.03 0.03 1.0 0.25 1.0 Open in a separate window a Expressed as the antibiotic and concentration (in micrograms per milliliter) from which it was isolated. b Tested at a 2:1 ratio and expressed as the concentration of amoxicillin. c Boldface values indicate a fourfold or greater increase in the MIC compared with that for the parent strain.

Techniques: Control